Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;20(3):176-178.

Current and Emerging Treatments for Autoimmune Hepatitis

Ethan M Weinberg  1
Affiliations

Current and Emerging Treatments for Autoimmune Hepatitis

Ethan M Weinberg. Gastroenterol Hepatol (N Y). 2024 Mar.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Halliday N, Dyson JK, Thorburn D, Lohse AW, Heneghan MA. Review article: experimental therapies in autoimmune hepatitis. Aliment Pharmacol Ther. 2020;52(7):1134–1149. - PubMed
    1. Jalal MI, Brahmbhatt M, Green K, Weinberg EM, Lammert C, Bittermann T. Autoimmune hepatitis and metabolic syndrome-associated disease development: a U.S. cohort study. Aliment Pharmacol Ther. 2022;56(7):1183–1193. - PubMed
    1. Liberal R, de Boer YS, Heneghan MA. Established and novel therapeutic options for autoimmune hepatitis. Lancet Gastroenterol Hepatol. 2021;6(4):315–326. - PubMed
    1. Manns MP, Woynarowski M, Kreisel W et al. European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198–1206. - PubMed
    1. Snijders RJALM, Stoelinga AEC, Gevers TJG Dutch Autoimmune Hepatitis Working Group. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis [published online December 14, 2023]. J Hepatol. doi:10.1016/j. jhep.2023.11.032. - PubMed

LinkOut - more resources